Clinical Trial Update: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial of autologous tumor-infiltrating lymphocytes (MDA-TIL) in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• MDA-TIL (autologous tumor-infiltrating lymphocytes)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-17